AstraZeneca (AZN) Share Forecast & Price Target

Compare

805 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AZN Analyst Ratings

Moderate Buy

10 Buy

2 Hold

1 Sell

Based on 13 analysts giving stock ratings to

AstraZeneca

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

13,917.15p

▲(11.05% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is 13,917.15p with a high forecast of 18,000.00p and a low forecast of 10,500.00p. The average price target represents a 11.05% change from the last price of 12,532.00p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10245":"10,245p","12184":"12,184p","14123":"14,123p","16062":"16,062p","18001":"18,001p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">18K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13917.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">14K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">11K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10245,12184,14123,16062,18001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12436,12864,13292,13720,14148,14576,15004,15432,15860,16288,16716,17144,17572,{"y":18000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12436,12549.934615384615,12663.86923076923,12777.803846153845,12891.738461538462,13005.673076923076,13119.607692307693,13233.542307692307,13347.476923076923,13461.411538461538,13575.346153846154,13689.280769230769,13803.215384615385,{"y":13917.15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12436,12287.076923076924,12138.153846153846,11989.23076923077,11840.307692307691,11691.384615384615,11542.461538461539,11393.538461538461,11244.615384615385,11095.692307692309,10946.76923076923,10797.846153846154,10648.923076923076,{"y":10500,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11549.92,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10788.41,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10330.33,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10246.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11103.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11884.96,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11287.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10534.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10500.63,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10329.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11026.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11850,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12436,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target18,000p

Average Price Target13,917p

Lowest Price Target10,500p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Leuchten

UBS

10,900p→15,000p

Buy

19.69%

Upside

Upgraded

10/26/25

Positive Report for AstraZeneca (AZN) from Jefferies

Richard Vosser

J.P. Morgan

14,000p

Buy

11.71%

Upside

Reiterated

10/24/25

AstraZeneca (AZN) Receives a Buy from J.P. Morgan

Emmanuel Papadakis

Deutsche Bank

10,500p

Sell

-16.21%

Downside

Reiterated

10/22/25

Deutsche Bank Sticks to Its Sell Rating for AstraZeneca (AZN)

Luisa Hector

Berenberg Bank

14,200p→14,500p

Buy

15.70%

Upside

Reiterated

10/22/25

AstraZeneca (AZN) Gets a Buy from Berenberg Bank

David Evans

Kepler Capital

11,300p

Hold

-9.83%

Downside

Reiterated

10/22/25

Kepler Capital Sticks to Its Hold Rating for AstraZeneca (AZN)

Shirley Chen

Barclays

14,000p

Buy

11.71%

Upside

Reiterated

10/21/25

Sarita Kapila

Morgan Stanley

13,700p

Buy

9.32%

Upside

Reiterated

10/17/25

AstraZeneca (AZN) Gets a Buy from Morgan StanleyRating: Overweight; Price Target: £137/sh (Upside to PT: 9%)

Justin Smith

Bernstein

18,000p

Buy

43.63%

Upside

Reiterated

10/07/25

Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

15,163p

Buy

20.99%

Upside

Reiterated

10/07/25

AstraZeneca's Innovation and Strategic Positioning Reinforce Buy Rating Amidst TROPION-Breast02 Success

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

13,500p→14,500p

Buy

15.70%

Upside

Reiterated

10/07/25

Shore Capital Sticks to Its Buy Rating for AstraZeneca (AZN)

Veda Pharmyne

TR | OpenAI - 4o

12,052p→13,991p

Buy

11.64%

Upside

Reiterated

10/03/25

AI Generated ArticleAI Generated Article

Sachin Jain

Bank of America Securities

14,500p

Buy

15.70%

Upside

Reiterated

09/04/25

AstraZeneca's Promising Pipeline and Valuation: A Compelling Investment OpportunityWe flag multiple 2H25 reads, which while “smaller” peak sales accumulate to be meaningful (efzim alfa in HPP, Imfinzi VOLGA, ceralasertib in NSCLC, Fasenra COPD). Importantly, we also see readthrough into SERENA-4 conviction from Roche’s competing persevERA PIII trial due 4Q25E.

Steve Scala

TD Cowen

14,860p

Buy

18.58%

Upside

Reiterated

08/29/25

AstraZeneca's Promising Outlook: Buy Rating Backed by Baxdrostat's Potential and Strategic Positioning

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

13,500p

Buy

7.72%

Upside

Reiterated

07/29/25

Shore Capital Sticks to Their Buy Rating for AstraZeneca (AZN)

Benjamin Jackson CFA

Jefferies

10,900p

Hold

-13.02%

Downside

Reiterated

07/29/25

Jefferies Reaffirms Their Hold Rating on AstraZeneca (AZN)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Leuchten

UBS

10,900p→15,000p

Buy

19.69%

Upside

Upgraded

10/26/25

Positive Report for AstraZeneca (AZN) from Jefferies

Richard Vosser

J.P. Morgan

14,000p

Buy

11.71%

Upside

Reiterated

10/24/25

AstraZeneca (AZN) Receives a Buy from J.P. Morgan

Emmanuel Papadakis

Deutsche Bank

10,500p

Sell

-16.21%

Downside

Reiterated

10/22/25

Deutsche Bank Sticks to Its Sell Rating for AstraZeneca (AZN)

Luisa Hector

Berenberg Bank

14,200p→14,500p

Buy

15.70%

Upside

Reiterated

10/22/25

AstraZeneca (AZN) Gets a Buy from Berenberg Bank

David Evans

Kepler Capital

11,300p

Hold

-9.83%

Downside

Reiterated

10/22/25

Kepler Capital Sticks to Its Hold Rating for AstraZeneca (AZN)

Shirley Chen

Barclays

14,000p

Buy

11.71%

Upside

Reiterated

10/21/25

Sarita Kapila

Morgan Stanley

13,700p

Buy

9.32%

Upside

Reiterated

10/17/25

AstraZeneca (AZN) Gets a Buy from Morgan StanleyRating: Overweight; Price Target: £137/sh (Upside to PT: 9%)

Justin Smith

Bernstein

18,000p

Buy

43.63%

Upside

Reiterated

10/07/25

Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

15,163p

Buy

20.99%

Upside

Reiterated

10/07/25

AstraZeneca's Innovation and Strategic Positioning Reinforce Buy Rating Amidst TROPION-Breast02 Success

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

13,500p→14,500p

Buy

15.70%

Upside

Reiterated

10/07/25

Shore Capital Sticks to Its Buy Rating for AstraZeneca (AZN)

Veda Pharmyne

TR | OpenAI - 4o

12,052p→13,991p

Buy

11.64%

Upside

Reiterated

10/03/25

AI Generated ArticleAI Generated Article

Sachin Jain

Bank of America Securities

14,500p

Buy

15.70%

Upside

Reiterated

09/04/25

Steve Scala

TD Cowen

14,860p

Buy

18.58%

Upside

Reiterated

08/29/25

AstraZeneca's Promising Outlook: Buy Rating Backed by Baxdrostat's Potential and Strategic Positioning

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

13,500p

Buy

7.72%

Upside

Reiterated

07/29/25

Shore Capital Sticks to Their Buy Rating for AstraZeneca (AZN)

Benjamin Jackson CFA

Jefferies

10,900p

Hold

-13.02%

Downside

Reiterated

07/29/25

Jefferies Reaffirms Their Hold Rating on AstraZeneca (AZN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

1 Month

xxx

Success Rate

33/55 ratings generated profit

Average Return

+1.48%

downgraded a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +1.48% per trade.

3 Months

xxx

Success Rate

35/55 ratings generated profit

Average Return

+5.48%

downgraded a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +5.48% per trade.

1 Year

Matthew WestonUBS

Success Rate

32/35 ratings generated profit

Average Return

+15.34%

reiterated a buy rating 15 days ago

Copying Matthew Weston's trades and holding each position for 1 Year would result in 91.43% of your transactions generating a profit, with an average return of +15.34% per trade.

2 Years

xxx

Success Rate

32/35 ratings generated profit

Average Return

+22.79%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 91.43% of your transactions generating a profit, with an average return of +22.79% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AZN has received 28 Buy Ratings, 5 Hold Ratings, and 1 Sell Ratings. AZN average Analyst price target in the past 3 months is 13,917.15.

Each month's total comprises the sum of three months' worth of ratings.

AZN Financial Forecast

AZN Earnings Forecast

Next quarter’s earnings estimate for AZN is 1.72p with a range of 1.67p to 1.81p. The previous quarter’s EPS was 1.63p. AZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year AZN has Preformed in-line its overall industry.

AZN Sales Forecast

Next quarter’s sales forecast for AZN is 11.09B with a range of 10.92B to 11.36B. The previous quarter’s sales results were 10.82B. AZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year AZN has Preformed in-line its overall industry.

AZN Stock Forecast FAQ

What is GB:AZN’s average 12-month price target, according to analysts?

Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 13,917.15.

What is GB:AZN’s upside potential, based on the analysts’ average price target?

AstraZeneca PLC has 11.05% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AstraZeneca PLC a Buy, Sell or Hold?

AstraZeneca PLC has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 2 hold ratings and 1 sell ratings.

What is AstraZeneca PLC’s share price target?

The average share price target for AstraZeneca PLC is 13,917.15. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 18,000.00p ,and the lowest forecast is 10,500.00p. The average share price target represents 11.05% Increase from the current price of 12,532p.

What do analysts say about AstraZeneca PLC?

AstraZeneca PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of AstraZeneca PLC?

To buy shares of GB:AZN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

AstraZeneca (AZN) Share Forecast & Price Target

AZN Analyst Ratings

AZN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AstraZeneca

AZN Analyst Recommendation Trends

AZN Financial Forecast

AZN Earnings Forecast

AZN Sales Forecast

AZN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts